Tech Company Financing Transactions
Cognito Therapeutics Funding Round
On 3/5/2026, Cognito Therapeutics landed $105 million in Series C funding from IAG Capital Partners, Morningside Ventures and Starbloom Capital.
Transaction Overview
Company Name
Announced On
3/5/2026
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series C
Investors
IAG Capital Partners (Lead Investor)
Morningside Ventures (Lead Investor)
Starbloom Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support advancement of the Spectris platform into additional neurodegenerative indications through their network of brain health collaboratories beginning with WVU Rockefeller Neuroscience Institute.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
1218 Massachusetts Ave 200
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brent Vaughan
Chief Medical Officer
Tom Megerian
Chief Scientific Officer
Mihaly Hajos
President
Zach Malchano
Vice President
Divya Cohen
Browse more venture capital transactions:
Prev: 3/5/2026: PLD Space venture capital transaction
Next: 3/5/2026: emproof venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs